Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion

International Immunopharmacology

Volumn 7, Issue 2, 2007, Pages 140-151

  Talmadge, James E ^a   Hood, Keith C ^a   Zobel, Lori C ^a   Shafer, Laura R ^a   Coles, Melissa ^b   Toth, Bela ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Carcinogenesis; Celecoxib; Chemoprevention; Dendritic cell; Immature myeloid suppressor cell

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ARGINASE; CD11B ANTIGEN; CD4 ANTIGEN; CELECOXIB; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CARCINOGENESIS; CELL COUNT; CELL FUNCTION; CELL LOSS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; IMMATURE MYELOID SUPPRESSOR CELL; IMMUNOREGULATION; LARGE INTESTINE TUMOR; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

1,2-DIMETHYLHYDRAZINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTICARCINOGENIC AGENTS; ARGINASE; BREAST NEOPLASMS; CARCINOGENS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CONCANAVALIN A; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; INTESTINAL NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NITRIC OXIDE SYNTHASE TYPE II; PYRAZOLES; RNA, MESSENGER; SPLEEN; SULFONAMIDES;

EID: 33845997430     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.09.021     Document Type: Article

References (51)

1. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
2. Phillips R.K., Wallace M.H., Lynch P.M., Hawk E., Gordon G.B., Saunders B.P., et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50 (2002) 857-860
3. Wang D., and DuBois R.N. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31 (2004) 64-73
4. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7 (2001) 1048-1051
5. Salcedo R., Zhang X., Young H.A., Michael N., Wasserman K., Ma W.H., et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102 (2003) 1966-1977
6. Bottomly K. T cells and dendritic cells get intimate. Science 283 (1999) 1124-1125
7. Parhar R.S., and Lala P.K. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J Leukoc Biol 44 (1988) 474-484
8. Fu Y.X., Watson G.A., Kasahara M., and Lopez D.M. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. J Immunol 146 (1991) 783-789
9. Huang M., Stolina M., Sharma S., Mao J.T., Zhu L., Miller P.W., et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58 (1998) 1208-1216
10. Sharma S., Stolina M., Yang S.C., Baratelli F., Lin J.F., Atianzar K., et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9 (2003) 961-968
11. Yang L., Yamagata N., Yadav R., Brandon S., Courtney R.L., Morrow J.D., et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 111 (2003) 727-735
12. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164 (2000) 361-370
13. Guadagni F., Roselli M., Cosimelli M., Spila A., Cavaliere F., Arcuri R., et al. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. Int J Cancer 72 (1997) 949-954
14. Brown W.A., Skinner S.A., Malcontenti-Wilson C., Vogiagis D., and O'Brien P.E. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 48 (2001) 660-666
15. Wei M., Morimura K., Wanibuchi H., Shen J., Salim E.I., Moku M., et al. JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats. Int J Cancer 113 (2005) 354-358
16. Rao C.V., Indranie C., Simi B., Manning P.T., Connor J.R., and Reddy B.S. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62 (2002) 165-170
17. Jacoby R.F., Cole C.E., Tutsch K., Newton M.A., Kelloff G., Hawk E.T., et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60 (2000) 1864-1870
18. Lanza-Jacoby S., Miller S., Flynn J., Gallatig K., Daskalakis C., Masferrer J.L., et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomark Prev 12 (2003) 1486-1491
19. Zeytin H.E., Patel A.C., Rogers C.J., Canter D., Hursting S.D., Schlom J., et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 64 (2004) 3668-3678
20. Oshima M., Murai N., Kargman S., Arguello M., Luk P., Kwong E., et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61 (2001) 1733-1740
21. Jacoby R.F., Seibert K., Cole C.E., Kelloff G., and Lubet R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60 (2000) 5040-5044
22. Han C., and Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280 (2005) 24053-24063
23. Lim J.T., Piazza G.A., Han E.K., Delohery T.M., Li H., Finn T.S., et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58 (1999) 1097-1107
24. Kardosh A., Soriano N., Liu Y.T., Uddin J., Petasis N.A., Hofman F.M., et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 106 (2005) 4330-4338
25. Sombroek C.C., Stam A.G., Masterson A.J., Lougheed S.M., Schakel M.J., Meijer C.J., et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 168 (2002) 4333-4343
26. Kalinski P., Schuitemaker J.H., Hilkens C.M., and Kapsenberg M.L. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a + CD83 + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 161 (1998) 2804-2809
27. Beckebaum S., Zhang X., Chen X., Yu Z., Frilling A., Dworacki G., et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 10 (2004) 7260-7269
28. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64 (2004) 5839-5849
29. Vieira P.L., de Jong E.C., Wierenga E.A., Kapsenberg M.L., and Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 164 (2000) 4507-4512
30. Li Q., Pan P.Y., Gu P., Xu D., and Chen S.H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 64 (2004) 1130-1139
31. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202 (2005) 931-939
32. Kusmartsev S., Nefedova Y., Yoder D., and Gabrilovich D.I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172 (2004) 989-999
33. Miller F.R., and Heppner G.H. Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. J Natl Cancer Inst 63 (1979) 1457-1463
34. Miller F.R., Miller B.E., and Heppner G.H. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3 (1983) 22-31
35. Toth B., Malick L., and Shimizu H. Production of intestinal and other tumors by 1, 2-dimethylhydrazine dihydrochloride in mice. I. A light and transmission electron microscopic study of colonic neoplasms. Am J Pathol 84 (1976) 69-86
36. Sang H., Pisarev V.M., Munger C., Robinson S., Chavez J., Hatcher L., et al. Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity. Vaccine 21 (2003) 3019-3029
37. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., and Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50 (1966) 219-244
38. Angulo I., de las Heras F.G., Garcia-Bustos J.F., Gargallo D., Munoz-Fernandez M.A., and Fresno M. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95 (2000) 212-220
39. Melani C., Chiodoni C., Forni G., and Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102 (2003) 2138-2145
40. Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53 (2004) 64-72
41. Broxmeyer H.E., Sherry B., Cooper S., Lu L., Maze R., Beckmann M.P., et al. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol 150 (1993) 3448-3458
42. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., and Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64 (2004) 6337-6343
43. Bronte V., Wang M., Overwijk W.W., Surman D.R., Pericle F., Rosenberg S.A., et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 161 (1998) 5313-5320
44. Kusmartsev S., and Gabrilovich D.I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 74 (2003) 186-196
45. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65 (2005) 3044-3048
46. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166 (2001) 678-689
47. Billiau A.D., Fevery S., Rutgeerts O., Landuyt W., and Waer M. Transient expansion of Mac1 + Ly6-G + Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood 102 (2003) 740-748
48. Zea A.H., Rodriguez P.C., Culotta K.S., Hernandez C.P., DeSalvo J., Ochoa J.B., et al. l-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol 232 (2004) 21-31
49. Rossner S., Voigtlander C., Wiethe C., Hanig J., Seifarth C., and Lutz M.B. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 35 (2005) 3533-3544
50. Sinha P., Clements V.K., and Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65 (2005) 11743-11751
51. Iniguez M.A., Punzon C., and Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 163 (1999) 111-119